Dr McArthur talks to ecancer at ESMO 2024 about negative trial results from the phase three study CAPItello-290, looking at targeted treatment for triple negative breast cancer vs chemotherapy.

The study's primary endpoint was OS, which was not improved on, though capivasertib did show reduction in disease progression or death.